Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Key events next week - healthcare

Stock MarketsNov 23, 2018 01:09PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Key events next week - healthcare
  • Noteworthy events during the week of November 25 - December 1 for healthcare investors.
  • MONDAY (11/26): FDA action date for Loxo Oncology's (NASDAQ:LOXO) larotrectinib in NTRK fusion-positive solid tumors.
  • Genocea Biosciences (NASDAQ:GNCA): KOL event on personalized cancer immunotherapies, NYC.
  • WEDNESDAY (11/28): FDA action date for Catalyst Pharmaceuticals ' (NASDAQ:CPRX) Firdapse for LEMS and Astellas Pharma's (OTCPK:ALPMF) gilteritinib for FLT3-positive AML.
  • THURSDAY (11/29): American Epilepsy Society Annual Meeting, New Orleans (6 days). Marinus Pharmaceuticals (NASDAQ:MRNS): Data on ganaxolone in children with CDKL5 Deficiency Disorder and PCDH19-related epilepsy. GW Pharmaceuticals (NASDAQ:GWPH): Phase 3 Epiolex data, preclinical and Phase 1 cannabidiol data.
  • SATURDAY (12/1): American Society of Hematology (ASH) Annual Meeting, San Diego (4 days). Argenx (NASDAQ:ARGX): Phase 2 data on efgartimod in primary immune thrombocytopenia. TG Therapeutics (NASDAQ:TGTX): Updated data on U2. Sierra Oncology (NASDAQ:SRRA): Momelotinib data. Sunesis Pharmaceuticals (NASDAQ:SNSS): Vecabrutinib data. Atara Biotherapeutics (NASDAQ:ATRA): Off-the-shelf CAR-T therapies. MiRagen Therapeutics (NASDAQ:MGEN): Phase 1 data on cobomarsen. Bio-Path Holdings (NASDAQ:BPTH): Phase 2 data on BP1001 (prexigebersen). Acceleron Pharma (NASDAQ:XLRN): Phase 3 data on luspatercept in MDS and beta-thalassemia. Affimed (NASDAQ:AFMD): Six abstracts. Verastem Oncology (NASDAQ:VSTM): Eight abstracts. Daiichi Sankyo (OTCPK:DSKYF): Phase 1 data on valemetostat, Phase 3 data on quizartinib preclinical data in quizartinib + milademetan. Bluebird bio (NASDAQ:BLUE): Phase 3 data on lentiglobin in beta-thalassemia, Phase 1 data on lentiglobin in SCD, Phase 1 data on bb21217 in MM, Phase 1 data on BCL11a shRNAmiR in SCD. Allogene Therapeutics (NASDAQ:ALLO): Pipeline data. Global Blood Therapeutics (NASDAQ:GBT): Four abstracts in SCD, including voxelotor. Unum Therapeutics (NASDAQ:UMRX): Phase 1 data on ACTR707 (with rituximab) in CD20+ B cell lymphomas. Celgene (NASDAQ:CELG): More than 100 abstracts. GlycoMimetics (NASDAQ:GLYC): Phase 1/2 data on uproliselan + chemo in AML. NewLink Genetics (NASDAQ:NLNK): Phase 1 data on indoximod in AML. Xencor (NASDAQ:XNCR): Phase 1 data on XmAb 14045 in AML. ImmunoGen (NASDAQ:IMGN): IMGN779 and IMGN632 data. Celyad (NASDAQ:CYAD): Phase 1 data on CYAD-01 in AML. Fate Therapeutics (NASDAQ:FATE): Preclinical data on FT500, Phase 1 data on ProTmune, introduce FATE-NK100. Bellicum Pharmaceuticals (NASDAQ:BLCM): Eight abstracts on lead candidate rivo-cel (BPX-501). Magenta Therapeutics (NASDAQ:MGTA): Five abstracts on ADCs, Phase 2 data on MGTA-456. Actinium Pharmaceuticals (NYSEMKT:ATNM): Multiple abstracts on antibody-radiation conjugates, Phase 3 data on Iomab-B. Roche (OTCQX:RHHBY): Over 70 abstracts. Stemline Therapeutics (NASDAQ:STML): Four abstracts on Elzonris (tagraxofusp)(SL-401). Humanigen (OTCQB:HGEN): Preclinical data on lenzilumab + CART19 for preventing CRS. Novartis (NYSE:NVS): Multiple abstracts, update on Kymriah in DLBCL. Seattle Genetics (NASDAQ:SGEN): Phase 3 data on Adcetris in first-line CD30+ peripheral T-cell lymphoma. MorphoSys (NASDAQ:MOR): Phase 2 data on MOR208 and Phase 1/2a data on MOR202. ArQule (NASDAQ:ARQL): Phase 1 data on ARQ 531.
  • Now read: Erytech Pharma S.A. ADS 2018 Q3 - Results - Earnings Call Slides

Original article
Key events next week - healthcare

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email